Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients With Advanced Solid Tumors (5-STAR 1-01)

NCT06657222 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT06657222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06657222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients With Advanced Solid Tumors (5-STAR 1-01)
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 13, 2024
Completion date
December 31, 2028
Enrollment
250 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, crc, hnscc, nsclc, sclc, tnbc - triple-negative breast cancer